Medpace Holdings (MEDP) AI Stock Analysis
Medpace Holdings
(BMV:MEDP)
No summary available
Medpace Holdings (MEDP) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- MXN 18.24B
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 35.5
- Beta (1Y)
- -0.05
- Revenue Growth
- 8.18%
- EPS Growth
- 12.36%
- Country
- Mexico
- Employees
- 6,600
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Medpace Holdings Business Overview & Revenue Model
Company Description
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients thr...
Medpace Holdings Earnings Call Summary
The call was broadly positive. Medpace reported strong revenue, EBITDA, net income, EPS, bookings, backlog, cash flow, pipeline activity, win rates, utilization, and employee retention, and raised its 2026 outlook. The main challenges were elevated-but-manageable cancellations, uncertainty that delayed 2027 guidance, quarter-to-quarter margin volatility, lower current metabolic awards, and approximately $20 million of operating costs from the Cincinnati expansion in 2027.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, total revenue is now expected in the range of $2.835 billion to $2.855 billion, representing growth of 12% to 12.8% over 2025 total revenue of $2.53 billion; EBITDA is now expected in the range of $638 million to $652 million, representing growth of 14.4% to 16.9% compared to EBITDA of $557.7 million in 2025; net income is forecast in the range of $514 million to $524 million; the guidance assumes a full year 2026 effective tax rate of 19% to 19.5%, interest income of $22.9 million and 28.6 million diluted weighted average shares outstanding, with no additional share repurchases assumed; earnings per diluted share is now expected in the range of $17.97 to $18.32, based on foreign exchange rates as of September 30, 2026. Pass-through mix is expected to be “somewhere around where we finished the third quarter,” or “kind of 40% to 40.5% based on our current model,” while 2027 guidance will be provided at the time of Q4 reporting in February, with “no large disconnect” between analyst consensus estimates and current modeling, including about $20 million of operating costs from the Cincinnati expansion in 2027.
Medpace Holdings Risk Analysis
Medpace Holdings disclosed 37 risk factors in its most recent earnings report. Medpace Holdings reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksMedpace Holdings Peers Comparison
Overall Rating
DGX76Outperform
LH75Outperform
IQV74Outperform
ICLR69Neutral
CRL58Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| DGX | 76Outperform | $27.71B | 24.74 | 15.21% | 1.34% | 9.13% | 17.93% |
| LH | 75Outperform | $29.31B | 29.45 | 11.54% | 0.80% | 6.02% | 19.63% |
| IQV | 74Outperform | $44.06B | 32.13 | 21.82% | ― | 8.88% | 13.11% |
| ICLR | 69Neutral | $16.31B | 36.13 | 4.85% | ― | 0.67% | 43.70% |
| CRL | 58Neutral | $17.16B | -74.26 | -7.72% | ― | -0.74% | -268.79% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MX:MEDP | Medpace Holdings Inc | 7022.03 | 1142.03 | 19.42% | |
| CRL | Charles River Laboratories Intl | 359.41 | 180.55 | 100.94% | |
| ICLR | Icon Plc | 211.36 | 42.57 | 25.22% | |
| LH | Labcorp Holdings Inc. | 361.39 | 106.13 | 41.58% | |
| DGX | Quest Diagnostics | 251.82 | 75.94 | 43.18% | |
| IQV | IQVIA Holdings | 267.33 | 53.45 | 24.99% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.